Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Teishima

Showing results (191-200 of 240) with videos related to

Pageof 24
Sort By:
International Urology and Nephrology|March 22, 2022
Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agentsJun Teishima, Keisuke Goto, Yohei Sekino, et al.
Urologic Oncology|March 27, 2021
TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancerYohei Sekino, Xiangrui Han, Takashi Babasaki, et al.
JAMA Network Open|November 12, 2020
Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung CancersKiyofumi Shimoji, Takeshi Masuda, Kakuhiro Yamaguchi, et al.
Abdominal Radiology (New York)|May 26, 2018
Tubulocystic renal cell carcinoma: a review of literature focused on radiological findings for differential diagnosisYukiko Honda, Yuko Nakamura, Keisuke Goto, et al.
BMC Cancer|October 6, 2018
Uc.416 + A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinomaYohei Sekino, Naoya Sakamoto, Keisuke Goto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 3, 2025
Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for Castration-Resistant Prostate CancerNaoki Matsuyama, Kotaro Suzuki, Taisuke Tobe, et al.
BJU International|August 18, 2020
Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassificationYuki Kohada, Tetsutaro Hayashi, Ryan S Hsi, et al.
Oncology|June 26, 2020
TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell CarcinomaYohei Sekino, Xiangrui Han, Takashi Babasaki, et al.
IJU Case Reports|August 4, 2020
Pneumatosis cystoides intestinalis linked to sunitinib treatment for renal cell carcinomaHiroyuki Shikuma, Shogo Inoue, Tomoya Hatayama, et al.
Current Urology|September 11, 2023
Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinomaJun Teishima, Daiki Murata, Kazuma Yukihiro, et al.
Pageof 24

Showing results (191-200 of 240) with videos related to

Sort By:
Pageof 24
International Urology and Nephrology|March 22, 2022
Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agentsJun Teishima, Keisuke Goto, Yohei Sekino, et al.
Urologic Oncology|March 27, 2021
TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancerYohei Sekino, Xiangrui Han, Takashi Babasaki, et al.
JAMA Network Open|November 12, 2020
Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung CancersKiyofumi Shimoji, Takeshi Masuda, Kakuhiro Yamaguchi, et al.
Abdominal Radiology (New York)|May 26, 2018
Tubulocystic renal cell carcinoma: a review of literature focused on radiological findings for differential diagnosisYukiko Honda, Yuko Nakamura, Keisuke Goto, et al.
BMC Cancer|October 6, 2018
Uc.416 + A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinomaYohei Sekino, Naoya Sakamoto, Keisuke Goto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 3, 2025
Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for Castration-Resistant Prostate CancerNaoki Matsuyama, Kotaro Suzuki, Taisuke Tobe, et al.
BJU International|August 18, 2020
Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassificationYuki Kohada, Tetsutaro Hayashi, Ryan S Hsi, et al.
Oncology|June 26, 2020
TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell CarcinomaYohei Sekino, Xiangrui Han, Takashi Babasaki, et al.
IJU Case Reports|August 4, 2020
Pneumatosis cystoides intestinalis linked to sunitinib treatment for renal cell carcinomaHiroyuki Shikuma, Shogo Inoue, Tomoya Hatayama, et al.
Current Urology|September 11, 2023
Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinomaJun Teishima, Daiki Murata, Kazuma Yukihiro, et al.
Pageof 24